Research programme: antibodies for bone diseases - Galapagos/Novartis

Drug Profile

Research programme: antibodies for bone diseases - Galapagos/Novartis

Latest Information Update: 21 Jul 2010

Price : $50

At a glance

  • Originator ProSkelia
  • Developer Galapagos NV; Novartis
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Bone disorders

Most Recent Events

  • 21 Jul 2010 No development reported - Preclinical for Bone disorders in Europe (Parenteral)
  • 22 Dec 2006 Galapagos NV acquires ProStrakan's responsibilities for this research collaboration, as part of Galapagos' purchase of ProSkelia
  • 10 Oct 2006 Preclinical trials in Bone disorders in Europe (Unspecified)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top